Locomotion

Global Market for Unmanned Ground Vehicles (UGVs) 2022: Growing Demand in Civilian Applications Presents Opportunities

Retrieved on: 
Lunedì, Novembre 28, 2022
Internet of things, R, Acquisition, Artificial intelligence, UGV, Police, IOT, Row, Law enforcement, HRO, Bomb, Locomotion, Agriculture, Dros, Mining, UGV Interoperability Profile, Human, EOD, Safety, Rail transport

DUBLIN, Nov. 28, 2022 /PRNewswire/ --The "Global Market for Unmanned Ground Vehicles (UGVs)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 28, 2022 /PRNewswire/ --The "Global Market for Unmanned Ground Vehicles (UGVs)" report has been added to ResearchAndMarkets.com's offering.
  • Apart from drivers and restraints, opportunity in humanitarian relief operation (HRO) and growing demand from civilian applications will create huge opportunities for vendors in the market.
  • In this report, the global UGV market has been segmented based on locomotion type, guidance, size, energy source, applications and region.
  • Based on applications, the UGV market has been segmented into military, agriculture, construction and mining, and civilian.

Global Market for Unmanned Ground Vehicles (UGVs) 2022: Increasing Demand for Detecting and Defeating Roadside Bombs Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Martedì, Novembre 22, 2022
Automotive, Other Automotive, Row, Agriculture, R, Police, Bomb, EOD, Dros, Law enforcement, Mining, Human, UGV Interoperability Profile, Safety, Acquisition, Artificial intelligence, Internet of things, HRO, UGV, Locomotion, IOT, Propane, Rail transport

The "Global Market for Unmanned Ground Vehicles (UGVs)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Unmanned Ground Vehicles (UGVs)" report has been added to ResearchAndMarkets.com's offering.
  • UGVs have the capability to provide safety to operators in various military, agriculture, mining and construction and civilian operations.
  • Increasing demand for detecting and defeating roadside bombs, gaining situational awareness, detecting chemical and radiological agents, increasing the standoff distance between soldiers, and potentially dangerous situations are the key factors driving the current UGV market growth.
  • In this report, the global UGV market has been segmented based on locomotion type, guidance, size, energy source, applications and region.

Qbtech and the AHSN Network Receive National Mental Health and Wellbeing Awards

Retrieved on: 
Giovedì, Novembre 17, 2022
Family, Mental Health, Health, Consumer, Teens, Children, FOCUS, Ageing, HSJ, Focus, National Mental Health Act, ADHD, Attention, Commercial, NHS England, Data, NHS, Mental health, Pain, Locomotion, Diagnosis, Avon and Wiltshire Mental Health Partnership NHS Trust, Patient, Medicine, Pharmaceutical industry

The Focus ADHD program, created by objective testing provider Qbtech and the AHSN Network, received the Best Innovative Mental Health Invention at the 2022 National Mental Health and Wellbeing Awards.

Key Points: 
  • The Focus ADHD program, created by objective testing provider Qbtech and the AHSN Network, received the Best Innovative Mental Health Invention at the 2022 National Mental Health and Wellbeing Awards.
  • Earlier this year, Qbtech and the AHSN network were winners of the prestigious Best Mental Health Partnership with the NHS' at the HSJ awards.
  • We greatly appreciate the chance to work closely with our partners at the AHSN Network.
  • The FOCUS ADHD National Program is a collaborative effort between Qbtech and the AHSN Network.

Global Electric Wheelchair Market Research Report (2022 to 2028) - Featuring Karman Healthcare, Kwang Yang Motor, Levo USA and Magic Mobility Among Others - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Ottobre 17, 2022
Other Manufacturing, Manufacturing, Adoption, News, Leg, Transport, Growth, Population, CAGR, Hospital, Wheelchair Foundation, WHO, World, Accident, COVID-19, Locomotion, Polio, World Health Organization, Hepatitis C, Wheelchair, Arthralgia, Taxicab, Marketing

The "Global Electric Wheelchair Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Electric Wheelchair Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global electric wheelchair market is anticipated to grow at a CAGR of around 9.2% during the forecast period 2021-2027.
  • For instance, joint pain causes by arthritis limits leg and lower body mobility, resulting in locomotion restrictions.
  • On the contrary, the increasing adoption of prosthetics is one of the major factors hindering the growth of the market.

Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease

Retrieved on: 
Martedì, Ottobre 11, 2022
Children, Biotechnology, Manufacturing, Health, Pharmaceutical, Research, Other Manufacturing, Genetics, Consumer, Science, Clinical Trials, CA, HSCT, Congress, ESGCT, CSF, Hope, Diagnosis, Locomotion, Krabbe disease, Lists of diseases, Peripheral nervous system, Cell, CGMP, Patient, Gene, Mesa, Sphingolipid, Dementia, Peripheral neuropathy, Multimedia, White matter, Clinical trial, European Society of Gene and Cell Therapy, Nerve, Psychosine, PNS, Hearing loss, AAV, Cerebrospinal fluid, Degenerative disease, Irritability, GALC, CEO, Hematopoietic stem cell transplantation, Incidence, Death, Safety, Natural history, CNS, M.D, Neurodegeneration, Brain, Plasma, ARM, Infant, Central nervous system, Nervous system, Pharmaceutical industry, Vaccine, Hearth, Krabbe, Forge

Clinical data support preclinical observations that this gene therapy approach after HSCT may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement.

Key Points: 
  • Clinical data support preclinical observations that this gene therapy approach after HSCT may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement.
  • Findings also support this novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to HSCT.
  • Krabbe disease is characterized by mutations in the GALC gene which lead to loss of motor function.
  • RESKUE a Phase 1/2 clinical trial to investigate the safety and efficacy of FBX-101 in patients with Infantile Krabbe disease.

Everi to Debut Player-Engaging Game Content and Newest Cabinet at Global Gaming Expo 2022

Retrieved on: 
Martedì, Ottobre 4, 2022
Gems, Diamond, Storm, Solution, Supernova, YouTube, Adventure, Fruit Ninja, Portrait, G2E, Empire, Technology, Industry, Television, Hilltop Holdings Inc., CEO, Mechanics, Imagination, Organic, Trilogy, Locomotion, Bullwinkle, Fiesta, NYSE, Communication, High Rollin (Jaira Burns song), Friends, Attention, Cut, Platinum, Company, IGaming Business, Video game, Amusement arcade, Everi Holdings

LAS VEGAS, Oct. 4, 2022 /PRNewswire/ -- Everi Holdings Inc. (NYSE: EVRI) ("Everi" or "the Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, and player loyalty solutions, will highlight its commitment to provide EVERIthing casino operators need to engage players with the debut of new games and a new gaming cabinet that deliver on the Company's promise of offering EVERIgame players will want to play at the 22nd annual Global Gaming Expo (G2E®), October 10-13, 2022. Everi will introduce the stunning Dynasty Vue™ – the Company's first form factor in its new Dynasty Series of game cabinets, as well as approximately 50 new original game themes and seven new licensed branded titles.

Key Points: 
  • By combining the benefits of three distinct cabinet form factors, it offers our game developers a platform to create entirely new games that captivate players' attention.
  • We are also excited to share with customers our content for the growing historical horse racing segment on both video and mechanical cabinets."
  • Everi will showcase the gold standard in slot tournament solutions and the latest iteration of its award-winning TournEventoffering, TournEvent Everiway.
  • Focused on player engagement and assisting our casino customers to operate more efficiently, the Company develops entertaining game content and gaming machines, gaming systems, and services for land-based and iGaming operators.

Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium

Retrieved on: 
Martedì, Agosto 30, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, GALC, Muscle weakness, Locomotion, Hematopoietic stem cell transplantation, Lipid, Peripheral neuropathy, Lists of diseases, Central nervous system, Krabbe disease, Brain, Entrepreneurship, Disease, Death, Peripheral nervous system, CGMP, Cell, Multimedia, Neurodegeneration, CET, Irritability, Hearing loss, Psychosine, UCBT, Clinical trial, Environment, Society, AAV, Patient, Pharmaceutical industry, Vaccine, Krabbe, Forge, Hearth, Metabolism

The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany.

Key Points: 
  • The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany.
  • The first patients data from the RESKUE clinical trial demonstrate that intravenous FBX-101 following UCBT has been safe and well tolerated through Day 180.
  • Notably, the data demonstrate an absence of humoral immune response against the vector and significantly increased GALC enzyme activity.
  • Through Day 180, the patient exhibited improved motor activity and normal brain development compared to previously reported transplanted patients with Krabbe disease.

Qbtech and The AHSN Network Shortlisted for Health Service Journal Partnership Award

Retrieved on: 
Mercoledì, Agosto 10, 2022
Science, Software, Research, Health, Mental Health, Data Management, Health Technology, Technology, FDA, Academic Health Science Networks, HSJ, Locomotion, Diagnosis, Attention, Health Service Journal, NHS England, Patient, Partnership, University Hospitals Bristol and Weston NHS Foundation Trust, NHS Improvement, News, NHS, Solution, Health, Medical device, Medicine, Hospital, Pharmaceutical industry, ADHD

Qbtech and The AHSN Network have been shortlisted for the 2022 Health Service Journal award for Best Partnership for QbTest, an objective assessment used in ADHD diagnosis.

Key Points: 
  • Qbtech and The AHSN Network have been shortlisted for the 2022 Health Service Journal award for Best Partnership for QbTest, an objective assessment used in ADHD diagnosis.
  • The teams at AHSN and Qbtech continue to make a real difference in improving access to quality care, diagnosis and treatment for those living with ADHD, shared Tony Doyle, Managing Director at Qbtech.
  • To be shortlisted for this overall partnership award highlights the far-reaching impact of our work together.
  • Following the thorough judging process, Qbtech and the AHSN Network were shortlisted, ahead of the official awards ceremony to be held later this year on November 17.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Lunedì, Agosto 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

Saint Leo University Opens a New Interactive Robotic & AI Lab by RobotLAB

Retrieved on: 
Lunedì, Agosto 1, 2022
K12, MIT Computer Science and Artificial Intelligence Laboratory, Intelligence, School, Student, Catholic (term), Artificial intelligence, SAN, Electronics, Partnership, Rotation, Gold, Best, Saint Leo University, Visual perception, Computer, Tampa Bay, Data science, Organization, Machine learning, Technology, Transport, Life, Program, Engineering, Computing, Locomotion, Automation, Game Changer, AI, Bachelor of Science, Edison Awards, Medicine, Tutoring, Management, Robotics, Benedictines

SAN FRANCISCO, Aug. 1, 2022 /PRNewswire/ -- Saint Leo University, one of the top ranked nonprofit universities in Florida, in partnership with RobotLAB, the leading educational robotics company, partnered to build an artificial intelligence and robotics lab on its residential campus in Pasco County, FL. 

Key Points: 
  • The Robotics & AI Lab by RobotLAB is a turnkey, state-of-the-art modular learning space designed to enable students' rotation between AI stations.
  • "We are excited to partner with Saint Leo University," said Elad Inbar, RobotLAB CEO.
  • We are excited to see Saint Leo University students prepare for their real post student life."
  • Saint Leo University is one of the largest Catholic universities in the nation, offering 62-degree programs to more than 15,800 students each year.